Gilead says remdesivir reduced risk of death in COVID-19 patients, more studies needed


  • World
  • Friday, 10 Jul 2020

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (COVID-19), during the outbreak of the coronavirus disease (COVID-19), in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake -/File Photo

(Reuters) - Gilead Sciences Inc said on Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients.

The company, which had initially released the data from the trial in April, said the finding requires confirmation in clinical trials.

Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In World

EU ends rule of law proceedings against Poland under liberal Tusk
Trump to return to New York courtroom for criminal hush money trial
Lamborghini bros no more: Crypto is creating a new wealth effect
Amazon driver fatally shoots person trying to steal vehicle at gunpoint, US cops say
Microsoft ties pay for top bosses to meeting cybersecurity goals
TikTok’s boss goes from reserved tech exec to Met Gala chair
Russia to practice tactical nuclear weapon scenario to deter West - defence ministry
Italy's white-collar mafia is making a business killing
The bystander’s role is changing in the era of livestreaming. North Carolina’s standoff shows how
Ukrainian drones kill six, injures 35 in Russia's Belgorod region, governor says

Others Also Read